Role of protein tyrosine kinase inhibitors in cancer therapeutics
Protein tyrosine kinases (PTKs) are critical in regulating cell growth and differentiation and are deeply involved in several cancers. PTK-inhibitors are mainly ATP-site directed and are finding use in the treatment of several cancers, and more than 30 such agents are now in phase I-III clinical tri...
Gespeichert in:
| Veröffentlicht in: | Indian journal of biochemistry & biophysics 2004-12, Vol.41 (6), p.273-280 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 280 |
|---|---|
| container_issue | 6 |
| container_start_page | 273 |
| container_title | Indian journal of biochemistry & biophysics |
| container_volume | 41 |
| creator | Bhise, S B Nalawade, Abhijit D Wadhawa, Hitesh |
| description | Protein tyrosine kinases (PTKs) are critical in regulating cell growth and differentiation and are deeply involved in several cancers. PTK-inhibitors are mainly ATP-site directed and are finding use in the treatment of several cancers, and more than 30 such agents are now in phase I-III clinical trials. The present review focuses mainly on the development of PTK inhibitors in clinical trials, with special emphasis on imatinib mesylate, a rationally designed, potent oral anticancer agent and selective inhibitor for Abl tyrosine kinase, including Bcr-Abl, C-kit and platelet-derived growth factor-receptor tyrosine kinases, which has been implicated in several malignancies, including chronic myeloid leukemia and gastrointestinal stromal tumour. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1034512895</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1034512895</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-281571904353632e2a3a8d3f6b231300b204cbcb90c14309a67b050a60f5c3ad3</originalsourceid><addsrcrecordid>eNo1jz1rwzAURTW0NGnav1A0djE86VmKPYbQLwgESjsbSX4mam3LleQh_76GptO9w-Fw7xVbA4IohIRqxW5T-gLQWkl1w1ZS1gCoyjXbvYeeeOj4FEMmP_J8jiH5kfi3H00i7seTtz6HmJbKnRkdRZ5PFM1Ec_Yu3bHrzvSJ7i-5YZ_PTx_71-JwfHnb7w7FJIXIhayE2ooaSlSoUZI0aKoWO20lCgSwEkpnna3BiRKhNnprQYHR0CmHpsUNe_zzLkt_Zkq5GXxy1PdmpDCnRgCWSsiqVgv6cEFnO1DbTNEPJp6b_9v4C0YrUYY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1034512895</pqid></control><display><type>article</type><title>Role of protein tyrosine kinase inhibitors in cancer therapeutics</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Bhise, S B ; Nalawade, Abhijit D ; Wadhawa, Hitesh</creator><creatorcontrib>Bhise, S B ; Nalawade, Abhijit D ; Wadhawa, Hitesh</creatorcontrib><description>Protein tyrosine kinases (PTKs) are critical in regulating cell growth and differentiation and are deeply involved in several cancers. PTK-inhibitors are mainly ATP-site directed and are finding use in the treatment of several cancers, and more than 30 such agents are now in phase I-III clinical trials. The present review focuses mainly on the development of PTK inhibitors in clinical trials, with special emphasis on imatinib mesylate, a rationally designed, potent oral anticancer agent and selective inhibitor for Abl tyrosine kinase, including Bcr-Abl, C-kit and platelet-derived growth factor-receptor tyrosine kinases, which has been implicated in several malignancies, including chronic myeloid leukemia and gastrointestinal stromal tumour.</description><identifier>ISSN: 0301-1208</identifier><identifier>PMID: 22900354</identifier><language>eng</language><publisher>India</publisher><subject>Administration, Oral ; Animals ; Antineoplastic Agents - pharmacology ; Binding Sites ; Cell Differentiation ; Cell Proliferation ; Clinical Trials as Topic ; Humans ; Models, Chemical ; Models, Molecular ; Neoplasms - drug therapy ; Neoplasms - enzymology ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Receptor, Epidermal Growth Factor - metabolism ; Recurrence ; Vascular Endothelial Growth Factor A - metabolism</subject><ispartof>Indian journal of biochemistry & biophysics, 2004-12, Vol.41 (6), p.273-280</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22900354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bhise, S B</creatorcontrib><creatorcontrib>Nalawade, Abhijit D</creatorcontrib><creatorcontrib>Wadhawa, Hitesh</creatorcontrib><title>Role of protein tyrosine kinase inhibitors in cancer therapeutics</title><title>Indian journal of biochemistry & biophysics</title><addtitle>Indian J Biochem Biophys</addtitle><description>Protein tyrosine kinases (PTKs) are critical in regulating cell growth and differentiation and are deeply involved in several cancers. PTK-inhibitors are mainly ATP-site directed and are finding use in the treatment of several cancers, and more than 30 such agents are now in phase I-III clinical trials. The present review focuses mainly on the development of PTK inhibitors in clinical trials, with special emphasis on imatinib mesylate, a rationally designed, potent oral anticancer agent and selective inhibitor for Abl tyrosine kinase, including Bcr-Abl, C-kit and platelet-derived growth factor-receptor tyrosine kinases, which has been implicated in several malignancies, including chronic myeloid leukemia and gastrointestinal stromal tumour.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Binding Sites</subject><subject>Cell Differentiation</subject><subject>Cell Proliferation</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Models, Chemical</subject><subject>Models, Molecular</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - enzymology</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Receptor, Epidermal Growth Factor - metabolism</subject><subject>Recurrence</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><issn>0301-1208</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jz1rwzAURTW0NGnav1A0djE86VmKPYbQLwgESjsbSX4mam3LleQh_76GptO9w-Fw7xVbA4IohIRqxW5T-gLQWkl1w1ZS1gCoyjXbvYeeeOj4FEMmP_J8jiH5kfi3H00i7seTtz6HmJbKnRkdRZ5PFM1Ec_Yu3bHrzvSJ7i-5YZ_PTx_71-JwfHnb7w7FJIXIhayE2ooaSlSoUZI0aKoWO20lCgSwEkpnna3BiRKhNnprQYHR0CmHpsUNe_zzLkt_Zkq5GXxy1PdmpDCnRgCWSsiqVgv6cEFnO1DbTNEPJp6b_9v4C0YrUYY</recordid><startdate>200412</startdate><enddate>200412</enddate><creator>Bhise, S B</creator><creator>Nalawade, Abhijit D</creator><creator>Wadhawa, Hitesh</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200412</creationdate><title>Role of protein tyrosine kinase inhibitors in cancer therapeutics</title><author>Bhise, S B ; Nalawade, Abhijit D ; Wadhawa, Hitesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-281571904353632e2a3a8d3f6b231300b204cbcb90c14309a67b050a60f5c3ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Binding Sites</topic><topic>Cell Differentiation</topic><topic>Cell Proliferation</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Models, Chemical</topic><topic>Models, Molecular</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - enzymology</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Receptor, Epidermal Growth Factor - metabolism</topic><topic>Recurrence</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bhise, S B</creatorcontrib><creatorcontrib>Nalawade, Abhijit D</creatorcontrib><creatorcontrib>Wadhawa, Hitesh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Indian journal of biochemistry & biophysics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bhise, S B</au><au>Nalawade, Abhijit D</au><au>Wadhawa, Hitesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of protein tyrosine kinase inhibitors in cancer therapeutics</atitle><jtitle>Indian journal of biochemistry & biophysics</jtitle><addtitle>Indian J Biochem Biophys</addtitle><date>2004-12</date><risdate>2004</risdate><volume>41</volume><issue>6</issue><spage>273</spage><epage>280</epage><pages>273-280</pages><issn>0301-1208</issn><abstract>Protein tyrosine kinases (PTKs) are critical in regulating cell growth and differentiation and are deeply involved in several cancers. PTK-inhibitors are mainly ATP-site directed and are finding use in the treatment of several cancers, and more than 30 such agents are now in phase I-III clinical trials. The present review focuses mainly on the development of PTK inhibitors in clinical trials, with special emphasis on imatinib mesylate, a rationally designed, potent oral anticancer agent and selective inhibitor for Abl tyrosine kinase, including Bcr-Abl, C-kit and platelet-derived growth factor-receptor tyrosine kinases, which has been implicated in several malignancies, including chronic myeloid leukemia and gastrointestinal stromal tumour.</abstract><cop>India</cop><pmid>22900354</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1208 |
| ispartof | Indian journal of biochemistry & biophysics, 2004-12, Vol.41 (6), p.273-280 |
| issn | 0301-1208 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1034512895 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
| subjects | Administration, Oral Animals Antineoplastic Agents - pharmacology Binding Sites Cell Differentiation Cell Proliferation Clinical Trials as Topic Humans Models, Chemical Models, Molecular Neoplasms - drug therapy Neoplasms - enzymology Protein-Tyrosine Kinases - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Recurrence Vascular Endothelial Growth Factor A - metabolism |
| title | Role of protein tyrosine kinase inhibitors in cancer therapeutics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T06%3A38%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20protein%20tyrosine%20kinase%20inhibitors%20in%20cancer%20therapeutics&rft.jtitle=Indian%20journal%20of%20biochemistry%20&%20biophysics&rft.au=Bhise,%20S%20B&rft.date=2004-12&rft.volume=41&rft.issue=6&rft.spage=273&rft.epage=280&rft.pages=273-280&rft.issn=0301-1208&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1034512895%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1034512895&rft_id=info:pmid/22900354&rfr_iscdi=true |